Candriam S.C.A. Paratek Pharmaceuticals, Inc. Transaction History

Candriam S.C.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 07, 2018	SELL	$9.05 - $10.95 $515,850 - $624,150	-57,000 Closed	0 $0
Q4 2017 Feb 07, 2018	SELL	$17.45 - $25.6 $1.85 Million - $2.71 Million	-106,000 Reduced 65.03%	57,000 $1.02 Million
Q3 2017 Nov 03, 2017	BUY	$18.9 - $28.2 $3.08 Million - $4.6 Million	163,000	163,000 $4.09 Million

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.